Under the Paperwork Reduction Act of 1995, no persons are required to respond

F

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

pplication Number		
iling Date		
irst Named Inventor Frase		er Shaw
rt Unit		
xaminer Name		
Hornou Docket Numb	or	EDVUDN1/2019

				-					
				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>				Releva	Columns,Lines w nt Passages or R s Appear	
	1	6038969		2000-03-21	Podlipec et a				
	2	5979313		1999-11-09	Fromm et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information pl	lease click the	Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Examiner Cite No Publication Number Kind Code! Date Name of Patentee or Ago of cited Document			Releva	Columns,Lines w nt Passages or R s Appear				
	1								
If you wis	h to a	dd additional U.S. Publ	lished Ap	plication citation	n information	please click the Ad	d button	Add	
				FOREIGN PAT	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,L where Relevant Passages or Rele Figures Appear	
	1	2317366	GB		1998-03-25				
If you wis	h to a	dd additional Foreign F	atent Do	cument citation	information p	please click the Add	button	Add	
			NON	I-PATENT LITE	RATURE DO	CUMENTS		Remove	

	Application Number		
NEODMATION DIOOLOGUEE	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Inventor Fraser Shaw	
Not for submission under 37 CFR 1.99)	Art Unit		
and or or it isoy	Examiner Name		
	Attorney Docket Numb	er	FRYHP0142US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

# Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year USPTO, GOV or MPEP 801.8.2 Either office that issued the document, by the bo-batter code (WIPO Standard ST3.3) are fragatese patent concerned, the shadoon of the year of the Emperor most procedule the serial number of the submotive consumest to countered. If which document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 3 Applicant is to place a check mark their if English language the instaltation is attacked.

Examiner Signature

# Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Filing Date Art Named Inventor Fraser Shaw Art Unit Examiner Name Attorney Docket Number FRY1910142US

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s):
---------------	----------	----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Don W. Bulson/	Date (YYYY-MM-DD)	2006-05-05
Name/Print	Don W. Bulson	Registration Number	28192

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.